National and Kapodistrian University of Athens
Εκτίμηση του ενδοκαρδιακού ορίου και της μυοκαρδιακής αιμάτωσης με ηχωκαρδιογραφικά μέσα αντίθεσης
Abstract
dc:descriptionBackground. Evaluation of wall motion abnormalities and myocardial perfusion with the use of echocardiographic contrast agents have several clinical applications and are of great value in specific clinical settings such as chronic ischaemia and acute myocardial infarction (AMI)Aim. To study intravenous Echogen, Sonovue and Levovist contrast agents in different clinical settings in order to assess ischaemia in patients with chronic and acute coronary artery disease during stress echocardiography.Methods. Chronic coronary artery disease: 56 patients undergoing dobutamine or arbutamine stress echocardiography for known or suspected coronary artery disease were studied. Echocardiographic analysis of wall motion score index and endocardial border detection (EBD) was performed at rest and at peak stress before and after intravenous injection of Echogen or Sonovue,. We analyzed all 22 myocardial segments and three regions (anterior, inferior and lateral) in the parasternal long and short-axis and apical 4 and 2 chamber views at rest and peak stress. Acquisition was performed in fundamental imaging. We used the 4-grade score system for wall motion analysis, while endocardial border delineation was graded from 0 to 3. In the thirty-eight patients that underwent arbutamine stress echocardiography EF was performed at rest and at peak stress before and after intravenous injection of Sonovue, by experienced and inexperienced observers.Furthermore in 20 patients with possible chronic ischaemia and previous coronary artery bypass in the last ten years with the use of left mammary artery graft on the left anterior descending artery we evaluated the feasibility of contrast echocardiography with the use of Levovist in the evaluation of patency and flow reserve of the arterial graft.Acute coronary artery disease: We studied 14 patients with AMI. Both low dose dobutamine stress echocardiography (LDDSE) and myocardial contrast echocardiography MCE with Levovist were performed after primary PTCA. The viability gold standard was a recovery of contractility detected at echocardiography 2 months later.Results Chronic coronary artery disease: With the use of Echogen there was an overall improvement of the delineation in 15/22 (68%) myocardial segments at rest, and in 21/22 (95%) at peak stress (p < 0.005). Ischemic wall motion abnormalities were apparent in 46/396 segments (12%) before and in 72/396 (18%) after EchoGen injection. Positive predictive value of the test in each segment compared to the corresponding coronary artery increased from 75 to 93% and negative predictive value from 34 to 40%. The injection of EchoGen also corrected the diagnosis for coronary artery disease from negative to positive in three myocardial regions and from positive to negative in another. All three observers noted an improvement in endocardial border definition following Sonovue (p=<0.001). At baseline, there was a significant difference in wall motion score index between experienced and inexperienced observers at rest (p=0.01) and at peak stress (p=0.001). Following Sonovue administration this was no longer significant (p=0.07, p=0.114). Intra-observer variability of end diastolic, end systolic volumes (ESV) and EF improved following contrast (p<0.05) at rest and during stress.Regarding the evaluation of patency of the LIMA graft on the LAD results showed that using the supraclavicular approach we obtained the visualization of the graft at rest in all patients (100%) and using the parastrernal approach in 19 out of 20 (95%) even without contrast injection. At rest the diastolic and systolic peak flow velocities were 0.368±0.129m/s and 0.413±0.133m/s; their ratio (diastolic/systolic) was 0.891±0.0701. The overall and diastolic velocity time integrals were 0.1571±0.0645m and 0.1426±0.0546m. After dipyridamole infusion we observed in all patients an increase in diastolic and systolic peak flow velocities as expected by 0.573±0.11m/s (p<0.005) and 0.71±0.317 m/s (p<0.005). Contrast injection at rest and after peak dipyridamole infusion showed better and clearer doppler signal of the graft allowing an easier evaluation of the velocity curves in all patients. In fact using the association dipyridamole-levovist the velocity ratio and the total and diastolic velocity time integral values were 1.0203±0.338 (p<0.05), 0.3392±0.141m (p<0.05) and 0.2269±0.111m (p<0.05).Acute coronary artery disease: For LDDSE, the sensitivity was 91%, the specificity 71% and the positive and negative predictive values were 93 and 64% respectively. For MCE, the sensitivity was 94%, the specificity 44%, the positive predictive value 89%, and the negative predictive value 59%. The two tests agreed in 81% of the cases. Stress echocardiography and contrast echocardiography agreed in 81% of cases.Conclusion: EchoGen and Sonovue injections improved endocardial border delineation and diagnostic accuracy in the evaluation of coronary artery disease during dobutamine stress echocardiography. The use of Sonovue also reduced intra-observer variability of EF% at rest and during peak arbutamine infusion. In the evaluation of the patency rate and flow reserve of the internal mammary artery graft this new approach seems to be valid and helps to better select patients who really need angiography.LDDSE has a very good positive accuracy; it has an acceptable negative predictive value and is relatively cheap. On the other hand, MCE has a good positive accuracy, but a low negative accuracy and carries a high cost. The integration of these two tests, which are too expensive in clinical practice, could improve our comprehension of the post-PTCA pathophysiology.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Calachanis, Marco
- Καλαχάνης, Μάρκος
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39907